Skip to main content

CG Oncology, Inc.

corporate_fare Company Profile

CG Oncology, Inc.

CGON·NASDAQ·Life Sciences·CIK 0001991792

The company is a late-stage clinical biopharmaceutical company that develops and commercializes cretostimogene grenadenorepvec (cretostimogene). Cretostimogene is an investigational oncolytic immunotherapy designed to eliminate cancer cells directly through selective replication and indirectly by activating an anti-tumor immune response. It is being developed as a potential backbone therapy for patients with bladder cancer. Cretostimogene is currently in clinical development for treating high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), which could address up to 150,000 patients. The company is evaluating cretostimogene as a monotherapy in BOND-003 Cohort C, an ongoing Phase 3 clinical trial for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without Ta/T1 disease. Enrollment for this cohort is complete, and data was reported in September 2025. This trial formed the basis for the Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for the initial indication, which began in the fourth quarter of 2025 and is expected to be completed in 2026. Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for high-risk BCG-unresponsive NMIBC with CIS with or without Ta or T1 papillary tumors. In April 2024, the company also started BOND-003 Cohort P, an exploratory study of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with only Ta/T1 disease. Initial data from Cohort P was reported at the 2025 AUA Annual Meeting, with further data reported at the Society of Urologic Oncology (SUO) 26th Annual Meeting in December 2025.

CG Oncology, Inc. (NASDAQ:CGON) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CGON at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CGON spans 4, 8-K, 144, 10-Q.

Recent high-impact activity:

  • CG Oncology CEO Arthur Kuan Buys $2.37M of Stock in Open Market
  • CG Oncology's PIVOT-006 Hits Primary Endpoint: 68% Recurrence Risk Cut, BLA Set for March 2027
  • Phase 3 Win: Cretostimogene Cuts Bladder Cancer Recurrence Risk 68%
  • Q3 Net Loss Widens to $56.9M as PIVOT-006 Topline Data Nears This Month
  • Former President & COO Ambaw Bellete Plans $696K Stock Sale, Extending $22.5M Post-Departure Liquidation

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.04M
Net Income
-$161M
Diluted EPS
-$2.08
Op. Cash Flow
-$132.35M
Free Cash Flow
-$132.48M
Gross Profit
-$607K
Operating Income
-$190.77M
Cash & Equivalents
$32.49M
Total Debt
$3M
Debt / Equity
0.00×
Net Margin
-39.85×
Shares Outstanding
80.69M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-079498

Short Interest & Short Volume

10.96 days to cover

FINRA reported short interest of 9,215,844 shares in CGON as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 11.0 days to cover at its recent average daily volume. On November 20, 2026, 54.9% of CGON volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,215,844 shares as of October 30, 2026
Change vs prior period▲ 3.9%
Days to cover10.96 at avg daily volume of 840,614
Daily short volume (FINRA facilities)54.9% of 692,821 shares on November 20, 2026
5-day average short volume52.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CGON, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raiseATM program

ATM Program Upsized by $500M · Immediate Dilution of $55.92 Per Share

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$79.5 +0.04% today
52-week range · as of 2026-11-18 $37.01 – $93.95
Market cap
$7.1B
Volume
1.7M (1.0× avg)
3-mo avg 1.6M
Live data · 2026-11-22 03:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGON - Latest Insights

CGON
Nov 18, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $79.68
Real-time Price: $79.50 info
Change: -$0.180 (-0.23%) info
Market Cap: $7.098B info
CGON
Nov 16, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $99.10
Real-time Price: $79.50 info
Change: -$19.60 (-20%) info
Market Cap: $7.098B info
CGON
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $100.01
Real-time Price: $79.50 info
Change: -$20.51 (-21%) info
Market Cap: $7.098B info
CGON
Nov 06, 2026, 8:15 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $64.80
Real-time Price: $79.50 info
Change: +$14.70 (+23%) info
Market Cap: $7.098B info
CGON
Aug 07, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $75.10
Real-time Price: $79.50 info
Change: +$4.40 (+6%) info
Market Cap: $7.098B info
CGON
Aug 06, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $79.50 info
Change: +$7.99 (+11%) info
Market Cap: $7.098B info
CGON
Aug 06, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $79.50 info
Change: +$7.99 (+11%) info
Market Cap: $7.098B info
CGON
Aug 06, 2026, 8:22 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $79.50 info
Change: +$7.99 (+11%) info
Market Cap: $7.098B info
CGON
Aug 06, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $79.50 info
Change: +$7.99 (+11%) info
Market Cap: $7.098B info
CGON
May 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $64.30
Real-time Price: $79.50 info
Change: +$15.20 (+24%) info
Market Cap: $7.098B info
CGON
May 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $69.53
Real-time Price: $79.50 info
Change: +$9.97 (+14%) info
Market Cap: $7.098B info
CGON
May 11, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $69.32
Real-time Price: $79.50 info
Change: +$10.18 (+15%) info
Market Cap: $7.098B info
CGON
May 08, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $69.62
Real-time Price: $79.50 info
Change: +$9.88 (+14%) info
Market Cap: $7.098B info
CGON
May 08, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $69.10
Real-time Price: $79.50 info
Change: +$10.40 (+15%) info
Market Cap: $7.098B info
CGON
May 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $69.10
Real-time Price: $79.50 info
Change: +$10.40 (+15%) info
Market Cap: $7.098B info
CGON
Apr 13, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $68.60
Real-time Price: $79.50 info
Change: +$10.90 (+16%) info
Market Cap: $7.098B info
CGON
Feb 27, 2026, 9:00 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $57.00
Real-time Price: $79.50 info
Change: +$22.50 (+39%) info
Market Cap: $7.098B info
CGON
Feb 27, 2026, 8:45 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $57.00
Real-time Price: $79.50 info
Change: +$22.50 (+39%) info
Market Cap: $7.098B info
CGON
Feb 27, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $57.00
Real-time Price: $79.50 info
Change: +$22.50 (+39%) info
Market Cap: $7.098B info
CGON
Jan 13, 2026, 4:51 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $52.16
Real-time Price: $79.50 info
Change: +$27.34 (+52%) info
Market Cap: $7.098B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets